Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Gegenanzeigen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.3 · PDF-Seite 4
HOS-086138 · Präparat HOS-083284
Concomitant medicinal product levels increased or decreased
1-Adrenoreceptor Alfuzosin Increased plasma concentrations of alfuzosin
Antagonist which may lead to severe hypotension (see
section 4.5).
Analgesics Pethidine, Increased plasma concentrations of
propoxyphene norpethidine and propoxyphene. Thereby,
increasing the risk of serious respiratory
depression or haematologic abnormalities, or
other serious adverse effects from these agents.
Antianginal Ranolazine Increased plasma concentrations of ranolazine
which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Anticancer Neratinib Increased plasma concentrations of neratinib
which may increase the potential for serious
and/or life-threatening reactions including
hepatotoxicity (see section 4.5).
Venetoclax Increased plasma concentrations of venetoclax.
Increased risk of tumor lysis syndrome at the
dose initiation and during the dose-titration
phase (see section 4.5).
Antiarrhythmics Amiodarone, bepridil, Increased plasma concentrations of amiodarone,
dronedarone, bepridil, dronedarone, encainide, flecanide,
encainide, flecanide, propafenone, quinidine. Thereby, increasing the
propafenone, quinidine risk of arrhythmias or other serious adverse
reactions from these agents.
Antibiotic Fusidic Acid Increased plasma concentrations of fusidic acid
and ritonavir.
Anti-gout Colchicine Potential for serious and/or life-threatening
reactions in patients with renal and/or hepatic
impairment (see sections 4.4 and 4.5).
Antihistamines Astemizole, Increased plasma concentrations of astemizole
terfenadine and terfenadine. Thereby, increasing the risk of
serious arrhythmias from these agents.
Antipsychotics/ Lurasidone Increased plasma concentrations of lurasidone
Neuroleptics which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Clozapine, pimozide Increased plasma concentrations of clozapine
and pimozide. Thereby, increasing the risk of
serious haematologic abnormalities, or other
serious adverse effects from these agents.
Quetiapine Increased plasma concentrations of quetiapine
which may lead to coma. The concomitant
administration with quetiapine is
contraindicated (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): propoxyphene (HOS-086140) quetiapine (HOS-086150) encainide (HOS-086145) alfuzosin (HOS-086139) propafenone (HOS-084530) dronedarone (HOS-086144) fusidic acid (HOS-086146) bepridil (HOS-085612) quinidine (HOS-085593) neratinib (HOS-086142) venetoclax (HOS-086143) lead (HOS-085592) pimozide (HOS-085600) colchicine (HOS-086147) astemizole (HOS-085608) clozapine (HOS-086149) amiodarone (HOS-085596) terfenadine (HOS-085607) lurasidone (HOS-086148) ranolazine (HOS-086141)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage f9fe97979894eedcce9660008265f9fc818cdb3984974bb2555b6c5e5869e4e5 · Zeichen 902–5292 im Abschnitt
Gegenanzeigen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 35
HOS-086387 · Präparat HOS-083284
Concomitant medicinal product levels increased or decreased
1-Adrenoreceptor Alfuzosin Increased plasma concentrations of alfuzosin
Antagonist which may lead to severe hypotension (see
section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfuzosin (HOS-086139) lead (HOS-085592)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage c9fa672c902cb6517f3ca9e9b17d7d3f3f5c99de9c69fb60e9f257626db3a4b8 · Zeichen 846–1177 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 12
HOS-086189 · Präparat HOS-083284
Alpha1 -Adrenoreceptor
Antagonist
Alfuzosin Ritonavir co-administration is likely to result in increased plasma concentrations of
alfuzosin and is therefore contraindicated (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfuzosin (HOS-086139)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage ca60d78e265932e01705990e1754dd69620d408237846ec43ef13f88b9e371c8 · Zeichen 9103–9358 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 44
HOS-086404 · Präparat HOS-083284
Alpha1 -Adrenoreceptor
Antagonist
Alfuzosin Ritonavir co-administration is likely to result in increased plasma concentrations of
alfuzosin and is therefore contraindicated (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfuzosin (HOS-086139)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 84863794a540e561a216548f45a792ab6743a14848fcdf9139a33639ffd37f03 · Zeichen 9343–9608 im Abschnitt
Gegenanzeigen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.3 · PDF-Seite 5
HOS-108791 · Präparat HOS-093083
Concomitant medicinal product levels increased
Alpha1-adrenoreceptor Alfuzosin Increased plasma concentrations of
antagonist alfuzosin which may lead to severe
hypotension. The concomitant
administration with alfuzosin is
contraindicated (see section 4.5).
Antianginal Ranolazine Increased plasma concentrations of
ranolazine which may increase the
potential for serious and/or life-
threatening reactions (see section 4.5).
Antiarrhythmics Amiodarone, dronedarone Increased plasma concentrations of
amiodarone and dronedarone. Thereby,
increasing the risk of arrhythmias or
other serious adverse reactions (see
section 4.5).
Antibiotic Fusidic Acid Increased plasma concentrations of
fusidic acid. The concomitant
administration with fusidic acid is
contraindicated in dermatological
infections (see section 4.5).
Anticancer Neratinib Increased plasma concentrations of
neratinib which may increase the
potential for serious and/or
life-threatening reactions (see section
4.5).
Venetoclax Increased plasma concentrations of
venetoclax. Increased risk of tumor lysis
syndrome at the dose initiation and
during the ramp-up phase (see section
4.5).
Anti-gout Colchicine Increased plasma concentrations of
colchicine. Potential for serious and/or
life-threatening reactions in patients with
renal and/or hepatic impairment (see
sections 4.4 and 4.5).
Antihistamines Astemizole, terfenadine Increased plasma concentrations of
astemizole and terfenadine. Thereby,
increasing the risk of serious
arrhythmias from these agents (see
section 4.5).
Antipsychotics/ Lurasidone Increased plasma concentrations of
Neuroleptics lurasidone which may increase the
potential for serious and/or life-
threatening reactions (see section 4.5).
Pimozide Increased plasma concentrations of
pimozide. Thereby, increasing the risk
of serious haematologic abnormalities,
or other serious adverse effects from this
agent (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfuzosin (HOS-086139) dronedarone (HOS-086144) fusidic acid (HOS-086146) neratinib (HOS-086142) venetoclax (HOS-086143) lead (HOS-085592) pimozide (HOS-085600) colchicine (HOS-086147) astemizole (HOS-085608) amiodarone (HOS-085596) terfenadine (HOS-085607) lurasidone (HOS-086148) ranolazine (HOS-086141)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 3af5f7da19ec49492414676af6b40d10b1389f87518dc00840ff964623d97870 · Zeichen 617–4755 im Abschnitt
Gegenanzeigen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 42
HOS-108987 · Präparat HOS-093083
Concomitant medicinal product levels increased
Alpha1- Alfuzosin Increased plasma concentrations of
adrenoreceptor alfuzosin which may lead to severe
antagonist hypotension. The concomitant
administration with alfuzosin is
contraindicated (see section 4.5).
Antianginal Ranolazine Increased plasma concentrations of
ranolazine which may increase the
potential for serious and/or life-
threatening reactions (see section 4.5).
Antiarrhythmics Amiodarone, dronedarone Increased plasma concentrations of
amiodarone and dronedarone. Thereby,
increasing the risk of arrhythmias or
other serious adverse reactions (see
section 4.5).
Antibiotic Fusidic Acid Increased plasma concentrations of
fusidic acid. The concomitant
administration with fusidic acid is
contraindicated in dermatological
infections (see section 4.5).
Anticancer Neratinib Increased plasma concentrations of
neratinib which may increase the
potential for serious and/or
life-threatening reactions (see section
4.5).
Venetoclax Increased plasma concentrations of
venetoclax. Increased risk of tumor
lysis syndrome at the dose initiation
and during the ramp-up phase (see
section 4.5).
Anti-gout Colchicine Increased plasma concentrations of
colchicine. Potential for serious and/or
life-threatening reactions in patients
with renal and/or hepatic impairment
(see sections 4.4 and 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfuzosin (HOS-086139) dronedarone (HOS-086144) fusidic acid (HOS-086146) neratinib (HOS-086142) venetoclax (HOS-086143) lead (HOS-085592) colchicine (HOS-086147) amiodarone (HOS-085596) ranolazine (HOS-086141)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 9293fe9ecfe32956533c5b772cc23612b4a6e3a500aeb3b328481fd78b786272 · Zeichen 583–3923 im Abschnitt
Gegenanzeigen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 77
HOS-109061 · Präparat HOS-093083
Concomitant medicinal product levels increased
Alpha1-adrenoreceptor Alfuzosin Increased plasma concentrations of
antagonist alfuzosin which may lead to severe
hypotension. The concomitant
administration with alfuzosin is
contraindicated (see section 4.5).
Antianginal Ranolazine Increased plasma concentrations of
ranolazine which may increase the
potential for serious and/or life-
threatening reactions (see section 4.5).
Antiarrhythmics Amiodarone, dronedarone Increased plasma concentrations of
amiodarone and dronedarone. Thereby,
increasing the risk of arrhythmias or other
serious adverse reactions (see section 4.5).
Antibiotic Fusidic Acid Increased plasma concentrations of fusidic
acid. The concomitant administration with
fusidic acid is contraindicated in
dermatological infections (see section
4.5).
Anticancer Neratinib Increased plasma concentrations of
neratinib which may increase the potential
for serious and/or life-threatening
reactions (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfuzosin (HOS-086139) dronedarone (HOS-086144) fusidic acid (HOS-086146) neratinib (HOS-086142) lead (HOS-085592) amiodarone (HOS-085596) ranolazine (HOS-086141)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 422bc2611cbcfafe8056f19a35bbcf976c0ce7cedb0696fe265110f54c2451df · Zeichen 589–2890 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 12
HOS-108860 · Präparat HOS-093083
Lopinavir: ↔
Ranitidine (150 mg single Ranitidine: ↔ No dose adjustment necessary
dose)
Alpha1 adrenoreceptor antagonist
Alfuzosin Alfuzosin: Concomitant administration of
Due to CYP3A inhibition by Kaletra and alfuzosin is contra-
lopinavir/ritonavir, concentrations indicated (see section 4.3) as
of alfuzosin are expected to alfuzosin-related toxicity,
increase. including hypotension, may be
increased.
Analgesics
Fentanyl Fentanyl: Careful monitoring of adverse
Increased risk of side-effects effects (notably respiratory
(respiratory depression, sedation) depression but also sedation) is
due to higher plasma recommended when fentanyl is
concentrations because of
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfuzosin (HOS-086139) ranitidine (HOS-085660) fentanyl (HOS-086196)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 96e190758dc45ac7fb4d963c731c6a1a9f40441a1d76efd2de728f20e2eab534 · Zeichen 7863–9031 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 48–49
HOS-109005 · Präparat HOS-093083
48
(Lopinavir/ritonavir resulted in a higher incidence of
400/100 mg BID) gastrointestinal adverse events and
elevations in triglycerides with the
or combination regimen without
increases in virological efficacy,
Fosamprenavir when compared with standard doses
(1400 mg BID) of fosamprenavir/ritonavir.
Concomitant administration of these
(Lopinavir/ritonavir medicinal products is not
533/133 mg BID) recommended.
Kaletra must not be administered
once daily in combination with
amprenavir.
Tipranavir/ritonavir Lopinavir: Concomitant administration of these
(500/100 mg BID) AUC: ↓ 55% medicinal products is not
Cmin: ↓ 70% recommended.
Cmax: ↓ 47%
Acid reducing agents
Omeprazole (40 mg Omeprazole: ↔ No dose adjustment necessary
QD)
Lopinavir: ↔
Ranitidine (150 mg Ranitidine: ↔ No dose adjustment necessary
single dose)
Alpha1 adrenoreceptor antagonist
Alfuzosin Alfuzosin: Concomitant administration of
Due to CYP3A inhibition by Kaletra and alfuzosin is contra-
lopinavir/ritonavir, concentrations indicated (see section 4.3) as
of alfuzosin are expected to alfuzosin-related toxicity, including
increase. hypotension, may be increased.
Analgesics
Fentanyl Fentanyl: Careful monitoring of adverse effects
Increased risk of side-effects (notably respiratory depression but
(respiratory depression, sedation) also sedation) is recommended when
due to higher plasma fentanyl is concomitantly
concentrations because of administered with Kaletra.
CYP3A4 inhibition by
lopinavir/ritonavir.
Antianginal
Ranolazine Due to CYP3A inhibition by The concomitant administration of
lopinavir/ritonavir, concentrations Kaletra and ranolazine is
of ranolazine are expected to contraindicated (see section 4.3).
increase.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfuzosin (HOS-086139) amprenavir (HOS-086183) ranitidine (HOS-085660) fentanyl (HOS-086196) fosamprenavir (HOS-086182) ranolazine (HOS-086141) tipranavir (HOS-086184) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 36be30eaedda7aebc321ed321c96a33a8b5f0e47dfdc414ad4d6358ff3954c0c · Zeichen 6614–9803 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 83–84
HOS-109078 · Präparat HOS-093083
83
Maraviroc Maraviroc: The dose of maraviroc should be
AUC: ↑ 295% decreased to 150 mg twice daily
Cmax: ↑ 97% during co-administration with
Due to CYP3A inhibition by Kaletra 400/100 mg twice daily.
lopinavir/ritonavir.
Integrase inhibitor
Raltegravir Raltegravir: No dose adjustment necessary
AUC: ↔
Cmax: ↔
C12: ↓ 30%
Lopinavir: ↔
Co-administration with other HIV protease inhibitors (PIs)
According to current treatment guidelines, dual therapy with protease inhibitors is generally not
recommended.
Fosamprenavir/ Fosamprenavir: Co-administration of increased
ritonavir (700/100 mg Amprenavir concentrations are doses of fosamprenavir (1400 mg
BID) significantly reduced. BID) with Kaletra oral solution
(533/133 mg BID) to protease
(Lopinavir/ritonavir inhibitor-experienced patients
400/100 mg BID) resulted in a higher incidence of
gastrointestinal adverse events and
or elevations in triglycerides with the
combination regimen without
Fosamprenavir increases in virological efficacy,
(1400 mg BID) when compared with standard doses
of fosamprenavir/ritonavir.
(Lopinavir/ritonavir Concomitant administration of these
533/133 mg BID) medicinal products is not
recommended.
Kaletra must not be administered
once daily in combination with
amprenavir.
Tipranavir/ritonavir Lopinavir: Concomitant administration of these
(500/100 mg BID) AUC: ↓ 55% medicinal products is not
Cmin: ↓ 70% recommended.
Cmax: ↓ 47%
Acid reducing agents
Omeprazole (40 mg Omeprazole: ↔ No dose adjustment necessary
QD)
Lopinavir: ↔
Ranitidine (150 mg Ranitidine: ↔ No dose adjustment necessary
single dose)
Alpha1 adrenoreceptor antagonist
Alfuzosin Alfuzosin: Concomitant administration of
Due to CYP3A inhibition by Kaletra and alfuzosin is contra-
lopinavir/ritonavir, concentrations indicated (see section 4.3) as
of alfuzosin are expected to alfuzosin-related toxicity, including
increase. hypotension, may be increased.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfuzosin (HOS-086139) protease (HOS-085623) maraviroc (HOS-086186) amprenavir (HOS-086183) ranitidine (HOS-085660) raltegravir (HOS-086187) fosamprenavir (HOS-086182) tipranavir (HOS-086184) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 262bfc7747e8af6a0bc31322576cc9f33731bdf23847197000d08285e923bde2 · Zeichen 5337–8975 im Abschnitt
Wechselwirkungen · Cialis
CIALIS 2.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-111255 · Präparat HOS-093485
Anti-hypertensives (including calcium channel blockers)
The co-administration of doxazosin (4 and 8 mg daily) and tadalafil (5 mg daily dose and 20 mg as a
single dose) increases the blood pressure-lowering effect of this alpha-blocker in a significant manner.
This effect lasts at least twelve hours and may be symptomatic, including syncope. Therefore this
combination is not recommended (see section 4.4).
In interaction studies performed in a limited number of healthy volunteers, these effects were not
reported with alfuzosin or tamsulosin. However, caution should be exercised when using tadalafil in
patients treated with any alpha-blockers, and notably in the elderly. Treatments should be initiated at
minimal dosage and progressively adjusted.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfuzosin (HOS-086139) doxazosin (HOS-088800) calcium (HOS-085615) tamsulosin (HOS-111257)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T14:23:00Z · SHA-256 545fdb0c46550348a52d431b0929b4f86d6314f2661c3c334d55f57753aad337 · Passage cabfad89c45f22b6c41a39f145cc850ce5c6ddf73cc1063f85fcb928cb8d0481 · Zeichen 2943–3697 im Abschnitt
Wechselwirkungen · Cialis
CIALIS 5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 20–21
HOS-111302 · Präparat HOS-093485
20
Anti-hypertensives (including calcium channel blockers)
The co-administration of doxazosin (4 and 8 mg daily) and tadalafil (5 mg daily dose and 20 mg as a
single dose) increases the blood pressure-lowering effect of this alpha-blocker in a significant manner.
This effect lasts at least twelve hours and may be symptomatic, including syncope. Therefore this
combination is not recommended (see section 4.4).
In interaction studies performed in a limited number of healthy volunteers, these effects were not
reported with alfuzosin or tamsulosin. However, caution should be exercised when using tadalafil in
patients treated with any alpha-blockers, and notably in the elderly. Treatments should be initiated at
minimal dosage and progressively adjusted.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfuzosin (HOS-086139) doxazosin (HOS-088800) calcium (HOS-085615) tamsulosin (HOS-111257)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T14:23:00Z · SHA-256 545fdb0c46550348a52d431b0929b4f86d6314f2661c3c334d55f57753aad337 · Passage 999d333c830ddb852b21bf2047f283bfeae5cc46ae36b00f2f883395cebd5d4c · Zeichen 2942–3700 im Abschnitt
Wechselwirkungen · Cialis
CIALIS 10 mg film-coated tablets CIALIS 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 35
HOS-111341 · Präparat HOS-093485
Anti-hypertensives (including calcium channel blockers)
The co-administration of doxazosin (4 and 8 mg daily) and tadalafil (5 mg daily dose and 20 mg as a
single dose) increases the blood pressure-lowering effect of this alpha-blocker in a significant manner.
This effect lasts at least twelve hours and may be symptomatic, including syncope. Therefore this
combination is not recommended (see section 4.4).
In interaction studies performed in a limited number of healthy volunteers, these effects were not
reported with alfuzosin or tamsulosin. However, caution should be exercised when using tadalafil in
patients treated with any alpha-blockers, and notably in the elderly. Treatments should be initiated at
minimal dosage and progressively adjusted.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfuzosin (HOS-086139) doxazosin (HOS-088800) calcium (HOS-085615) tamsulosin (HOS-111257)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T14:23:00Z · SHA-256 545fdb0c46550348a52d431b0929b4f86d6314f2661c3c334d55f57753aad337 · Passage cabfad89c45f22b6c41a39f145cc850ce5c6ddf73cc1063f85fcb928cb8d0481 · Zeichen 2946–3700 im Abschnitt
Wechselwirkungen · Levitra
Levitra 5 mg film-coated tablets Levitra10 mg film-coated tablets Levitra 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-111603 · Präparat HOS-093557
Based on the results of interaction studies conducted with vardenafil in patients with benign prostatic
hyperplasia (BPH) on stable tamsulosin, terazosin or alfuzosin therapy:
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfuzosin (HOS-086139) terazosin (HOS-111602) tamsulosin (HOS-111257)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-01-20T02:00:00Z · SHA-256 47e3580d78a6f70de1b067c00d9d64bdf57d13d70ada7a3e149ededb018a79a5 · Passage e89dd0f66ece4f75272abe6a87f0ea15b285f6d19bbf4c6b7255c3bd3f339091 · Zeichen 5315–5490 im Abschnitt
Wechselwirkungen · Levitra
Levitra 5 mg film-coated tablets Levitra10 mg film-coated tablets Levitra 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6–7
HOS-111604 · Präparat HOS-093557
6
• When vardenafil (film-coated tablets) was given at doses of 5, 10 or 20 mg on a background of
stable therapy with tamsulosin, there was no symptomatic reduction in blood pressure, although
3/21 tamsulosin treated subjects exhibited transient standing systolic blood pressures of less than
85 mmHg.
• When vardenafil 5 mg (film-coated tablets) was given simultaneously with terazosin 5 or 10 mg,
one of 21 patients experienced symptomatic postural hypotension. Hypotension was not observed
when vardenafil 5 mg and terazosin administration was separated by 6 hours.
• When vardenafil (film-coated tablets) was given at doses of 5 or 10 mg on a background of stable
therapy with alfuzosin, compared to placebo, there was no symptomatic reduction in blood
pressure.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): placebo (HOS-088378) alfuzosin (HOS-086139) terazosin (HOS-111602) tamsulosin (HOS-111257)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-01-20T02:00:00Z · SHA-256 47e3580d78a6f70de1b067c00d9d64bdf57d13d70ada7a3e149ededb018a79a5 · Passage 69afe73a796d7b234a1d58d0a6325dc01e54c6387845e7fbab8185f40207024d · Zeichen 5547–6368 im Abschnitt
Wechselwirkungen · Levitra
Levitra 5 mg film-coated tablets Levitra10 mg film-coated tablets Levitra 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-111605 · Präparat HOS-093557
Therefore, concomitant treatment should be initiated only if the patient is stable on his alpha-blocker
therapy. In those patients who are stable on alpha-blocker therapy, vardenafil should be initiated at the
lowest recommended starting dose of 5 mg. Levitra may be administered at any time with tamsulosin or
alfuzosin. With other alpha-blockers a time separation of dosing should be considered when vardenafil
is prescribed concomitantly (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfuzosin (HOS-086139) tamsulosin (HOS-111257)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-01-20T02:00:00Z · SHA-256 47e3580d78a6f70de1b067c00d9d64bdf57d13d70ada7a3e149ededb018a79a5 · Passage b42ce10ff174c38a800e79cdf0a5526667c9826467c294eea00149e1531b82b8 · Zeichen 6370–6829 im Abschnitt
Wechselwirkungen · Levitra
Levitra 10 mg orodispersible tablets · Abschnitt 4.5 · PDF-Seite 22
HOS-111644 · Präparat HOS-093557
Based on the results of interaction studies conducted with vardenafil in patients with benign prostatic
hyperplasia (BPH) on stable tamsulosin, terazosin or alfuzosin therapy:
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfuzosin (HOS-086139) terazosin (HOS-111602) tamsulosin (HOS-111257)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-01-20T02:00:00Z · SHA-256 47e3580d78a6f70de1b067c00d9d64bdf57d13d70ada7a3e149ededb018a79a5 · Passage e89dd0f66ece4f75272abe6a87f0ea15b285f6d19bbf4c6b7255c3bd3f339091 · Zeichen 5418–5593 im Abschnitt
Wechselwirkungen · Levitra
Levitra 10 mg orodispersible tablets · Abschnitt 4.5 · PDF-Seite 22
HOS-111645 · Präparat HOS-093557
• When vardenafil (film-coated tablets) was given at doses of 5, 10 or 20 mg on a background of
stable therapy with tamsulosin, there was no symptomatic reduction in blood pressure, although
3/21 tamsulosin treated subjects exhibited transient standing systolic blood pressures of less than
85 mmHg.
• When vardenafil 5 mg (film-coated tablets) was given simultaneously with terazosin 5 or 10 mg,
one of 21 patients experienced symptomatic postural hypotension. Hypotension was not observed
when vardenafil 5 mg and terazosin administration was separated by 6 hours.
• When vardenafil (film-coated tablets) was given at doses of 5 or 10 mg on a background of stable
therapy with alfuzosin, compared to placebo, there was no symptomatic reduction in blood
pressure.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): placebo (HOS-088378) alfuzosin (HOS-086139) terazosin (HOS-111602) tamsulosin (HOS-111257)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-01-20T02:00:00Z · SHA-256 47e3580d78a6f70de1b067c00d9d64bdf57d13d70ada7a3e149ededb018a79a5 · Passage 9fc2f00af7ff056097d9e0d078711bad9fc7dabad0a5f2be56e83e42b2325310 · Zeichen 5595–6413 im Abschnitt
Wechselwirkungen · Levitra
Levitra 10 mg orodispersible tablets · Abschnitt 4.5 · PDF-Seite 22
HOS-111646 · Präparat HOS-093557
Therefore, concomitant treatment should be initiated only if the patient is stable on his alpha-blocker
therapy. In those patients who are stable on alpha-blocker therapy, vardenafil should be initiated at the
lowest recommended starting dose of 5mg. Levitra may be administered at any time with tamsulosin or
alfuzosin. With other alpha-blockers a time separation of dosing should be considered when vardenafil
is prescribed concomitantly (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfuzosin (HOS-086139) tamsulosin (HOS-111257)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-01-20T02:00:00Z · SHA-256 47e3580d78a6f70de1b067c00d9d64bdf57d13d70ada7a3e149ededb018a79a5 · Passage 4623916e730642051025d4536caf9c0eac89efccc592dc42a8cbbe3fabfc42f0 · Zeichen 6415–6873 im Abschnitt
Gegenanzeigen · Reyataz
REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.3 · PDF-Seite 4
HOS-112044 · Präparat HOS-093615
Co-administration with medicinal products that are substrates of the CYP3A4 isoform of cytochrome
P450 and have narrow therapeutic windows (e.g., quetiapine, lurasidone, alfuzosin, astemizole,
terfenadine, cisapride, pimozide, quinidine, bepridil, triazolam, midazolam administered orally (for
caution on parenterally administered midazolam, see section 4.5), lomitapide, and ergot alkaloids,
particularly, ergotamine, dihydroergotamine, ergonovine, methylergonovine) (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): quetiapine (HOS-086150) alfuzosin (HOS-086139) methylergonovine (HOS-086155) cisapride (HOS-085610) lomitapide (HOS-086160) bepridil (HOS-085612) quinidine (HOS-085593) ergot alkaloids (HOS-108807) pimozide (HOS-085600) astemizole (HOS-085608) ergotamine (HOS-086154) terfenadine (HOS-085607) lurasidone (HOS-086148) ergonovine (HOS-086153) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 7b7b0f048824fcb784b546989cbc26fbf98af81b02e5d50ce08dc589e2545d88 · Zeichen 636–1122 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.